seco-duocarmycin SA

seco-Duocarmycin SA (sDSA) is a highly potent synthetic analog of the duocarmycin family of antitumor antibiotics. It functions as a DNA alkylating agent that selectively targets the N3 position of adenine within the minor groove of the DNA double helix. This site-specific alkylation induces significant DNA damage, leading to G2/M phase cell cycle arrest and subsequent apoptosis in cancer cells. Research presented at AACR 2024 highlights its potential as a therapeutic agent for glioblastoma multiforme (GBM), particularly when used in synergistic combination with proton radiation to overcome radio-chemo-resistance in aggressive brain tumors. While duocarmycins are frequently utilized as cytotoxic payloads in antibody-drug conjugates (ADCs), sDSA is being investigated as a standalone small molecule therapeutic in translational oncology.

Other names

seco-DSA